Shares of Ono Pharmaceutical Co. (OTCMKTS:OPHLF – Get Free Report) saw an uptick in trading volume on Tuesday after Zacks Research upgraded the stock from a hold rating to a strong-buy rating. 1,086 shares were traded during trading, an increase of 199% from the previous session’s volume of 363 shares.The stock last traded at $15.63 and had previously closed at $14.90.
Ono Pharmaceutical Price Performance
The company has a debt-to-equity ratio of 0.10, a current ratio of 3.02 and a quick ratio of 2.56. The company has a fifty day moving average of $14.42 and a 200-day moving average of $14.69. The firm has a market cap of $7.31 billion, a P/E ratio of 15.72 and a beta of 0.34.
About Ono Pharmaceutical
Ono Pharmaceutical Co, Ltd., founded in 1717 and headquartered in Osaka, Japan, is a research‐based pharmaceutical company specializing in the discovery, development and marketing of innovative therapies. With origins as a traditional pharmacy, Ono has grown into a global biopharmaceutical entity focused on delivering new treatment options across several therapeutic areas, including oncology, immunology, cardiovascular and antiviral diseases. The company conducts comprehensive research programs spanning early drug discovery through to clinical development.
One of Ono’s most recognized products is the immune checkpoint inhibitor nivolumab, marketed in collaboration with Bristol-Myers Squibb under the trade name Opdivo.
See Also
- Five stocks we like better than Ono Pharmaceutical
- Which Storage Stock Is Best Positioned to Win the AI Memory War?
- Tesla’s Delivery Surprise Was Big—Earnings Need to Be Bigger
- Why Johnson & Johnson’s Earnings Dip Looks Like a Buying Opportunity
- CPI Comes In Cool: Why It Could Revive These 3 Rate-Sensitive Stocks
Receive News & Ratings for Ono Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ono Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
